<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720288</url>
  </required_header>
  <id_info>
    <org_study_id>PSInCor-Acetazolamide</org_study_id>
    <nct_id>NCT03720288</nct_id>
  </id_info>
  <brief_title>Acetazolamide in Patients With Acute Heart Failure</brief_title>
  <acronym>ACETA</acronym>
  <official_title>Prospective Analysis Between Acetazolamide vs Placebo in Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Recent studies have suggested that the use of acetazolamide may assist in the
      vol- ume management of patients with decompensated heart failure (HF). However, prospective
      and randomized comparison in patients with HF and optimized diuretic therapy has not been
      described. Objective: The aim of this study was to evaluate the effectiveness and safety of
      the use of acetazolamide versus placebo in volume control in patients with decompensated HF.
      Methodology: For this, a unicentric, randomized, double blind and prospective study will be
      performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose,
      complications) of patients will be analyzed for safety and effectiveness. Expected results:
      The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for
      volume control in patients with decompensated HF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diuresis and negative water balance</measure>
    <time_frame>72 hours</time_frame>
    <description>The comparison between groups for diuresis and negative water balance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cases with worsening of renal function</measure>
    <time_frame>72 hours</time_frame>
    <description>worsening of renal function (increase of 0.5 mg / dl or 25% increase in relation to admission creatinine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with lowering of consciousness level</measure>
    <time_frame>72 hours</time_frame>
    <description>lowering of consciousness level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with circulatory assistance</measure>
    <time_frame>72 hours</time_frame>
    <description>need for mechanical circulatory assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with vasopressor</measure>
    <time_frame>72 hours</time_frame>
    <description>need for vasopressor or inotropic association</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with orotracheal intubation</measure>
    <time_frame>72 hours</time_frame>
    <description>need for orotracheal intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with arrhythmia</measure>
    <time_frame>72 hours</time_frame>
    <description>occurrence of sustained ventricular arrhythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases with acetazolamide side effects</measure>
    <time_frame>72 hours</time_frame>
    <description>need for suspension of acetazolamide due to side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cases of death</measure>
    <time_frame>72 hours</time_frame>
    <description>ocurrence of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Base excess</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated (base excess)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of bicarbonate</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of systolic and diastolic blood pressure</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of cardiac output</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of systolic volume</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of arterial lactate</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of BNP</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of troponin</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of sodium</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of potassium</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of creatinine</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of urea</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of all hemodynamic / metabolic parameters to be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women aged&gt; 18 years.

          -  Patients with LVEF ≤ 40% documented on echocardiography

          -  BNP&gt; 500 pg / mL

          -  Signed consent form.

        Exclusion Criteria:

          -  Pregnancy

          -  COPD

          -  Hepatical cirrhosis

          -  Known allergy to acetazolamide

          -  2nd or 3rd degree atrioventricular block.

          -  SBP &lt;90 mmHg or need for vasopressor / inotropic use.

          -  Body mass index greater than 40 kg / m2.

          -  Acute coronary syndrome.

          -  Orotracheal intubation.

          -  Presence of significant pericardial effusion.

          -  Left ventricular outflow tract obstruction.

          -  Serum creatinine&gt; 5.0 mg / dL, creatinine clearance &lt;10 mL / min or hemodialysis.

          -  Presence of 2 or more clinical / laboratory / radiological criteria of infection
             defined by:

               -  Fever

               -  Leukocyte&gt; 12,000 / mm3 or&gt; 10% of young forms,

               -  Disuria

               -  Productive cough

               -  Bacteremia

               -  Inflammatory / infectious skin lesions

               -  Abdominal pain with signs of peritonitis

               -  Radiological image of pneumonia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mucio Tavares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Clínica de Emergência</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Soeiro, MD</last_name>
    <phone>+551126615299</phone>
    <email>alexandre.soeiro@bol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Coração - HMFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Soeiro, MD</last_name>
      <phone>5511-2661-5299</phone>
      <email>alexandre.soeiro@bol.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

